Abstract
PURPOSE: Early after therapy, 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) imaging is not always reliable due to the influx of inflammatory cells while apoptosis imaging offers a direct and early measurement of therapy effects. This study uses an improved apoptosis probe ((99m)Tc-hAnxA5) in combination with [(18)F]FDG imaging to evaluate therapy response. PROCEDURES: Daudi tumor tissue was implanted in the spleen of SCID mice. Treatment was performed with adriamycin and cyclophosphamide. Sequential [(18)F]FDG-positron emission tomography (PET) was acquired over 6 days and (99m)Tc-hAnxA5-SPECT was performed before and 1 day after therapy. RESULTS: On day 1, therapy induced apoptosis was visualized with (99m)Tc-hAnxA5 without a measurable change in [(18)F]FDG uptake. [(18)F]FDG uptake decreased significantly on day 3 and was even more pronounced on day 6. CONCLUSION: In this preclinical model, (99m)Tc-hAnxA5 imaging was able to detect apoptosis before metabolic changes were measured. These results confirm the value of apoptosis imaging for therapy response and give more insight in [(18)F]FDG imaging and its parameters to evaluate response.
Original language | English |
---|---|
Pages (from-to) | 995-1002 |
Number of pages | 8 |
Journal | Molecular Imaging and Biology |
Volume | 13 |
Issue number | 5 |
DOIs | |
Publication status | Published - Oct 2011 |
Keywords
- Lymphoma
- Chemotherapy response
- MRI
- [(18)F]FDG and (99m)Tc-hAnxA5
- NON-HODGKINS-LYMPHOMA
- POSITRON-EMISSION-TOMOGRAPHY
- ANNEXIN-V
- CELL-DEATH
- TUMOR RESPONSE
- CANCER-THERAPY
- IN-VIVO
- CHEMOTHERAPY
- RADIOTHERAPY
- DAUDI